Oncotarget · 2018 · 18 citations · 36 references
MedicineOncologyPharmacologyApoptosisImmunotherapyMolecular OncologyApoptosis ResistanceBcl-2 Family ProteinsCancer Stem CellsIntrinsic Apoptotic PathwayReceptor Tyrosine Kinase SignalingTyrosine Kinase InhibitorsApoptosis InductionBruton Tyrosine KinaseBruton's Tyrosine Kinase InhibitorsCaspase CleavageMitochondrial Apoptosis PathwaysMitochondrial Apoptosis RegulationPro-apoptotic Bax ActivationTumor Initiating Cells
// Aya Maeda 1 , Yuki Nishida 1 , Marla Weetall 2 , Liangxian Cao 2 , Arthur Branstrom 2 , Jo Ishizawa 3 , Takenobu Nii 3 , Wendy D. Schober 3 , Yoshiaki Abe 4 , Kosei Matsue 4 , Mariko Yoshimura 1 , Shinya Kimura 1 and Kensuke Kojima 1 1 Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Saga University, Saga, Japan 2 PTC Therapeutics, South Plainfield, NJ, USA 3 Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA 4 Division of Hematology/Oncology, Department of Medicine, Kameda Medical Center, Kamogawa, Japan Correspondence to: Kensuke Kojima, email: kkojima@cc.saga-u.ac.jp Keywords: BMI-1; mantle cell lymphoma Received: November 30, 2017 Accepted: May 21, 2018 Published: June 19, 2018 ABSTRACT Despite the development of the novel Bruton tyrosine kinase inhibitor ibrutinib, mantle cell lymphoma (MCL) remains an incurable B-cell non-Hodgkin lymphoma. BMI-1 is required for the self-renewal and maintenance of MCL-initiating stem cells. Upregulation of BMI-1 has been reported in MCL patients, especially in those with refractory/relapsed disease. We studied the effects of a novel small-molecule selective inhibitor of BMI1 expression, PTC596, in MCL cells. Eight MCL cell lines and patient-derived samples were exposed to PTC596. PTC596 induced mitochondrial apoptosis, as evidenced by loss of mitochondrial membrane potential, caspase-3 cleavage, BAX activation, and phosphatidylserine externalization. There was a positive correlation between baseline BMI-1 protein levels and PTC596-induced apoptosis. p53 status did not affect sensitivity to PTC596. PTC596 effectively decreased BMI-1-expressing and tumor-initiating side population MCL cells (IC 50 : 138 nM) compared with ibrutinib, which modestly decreased side population cells. Interestingly, PTC596, reported to target cancer stem cells, decreased MCL-1 expression levels and antagonized ibrutinib-induced increase in MCL-1 expression, leading to synergistic apoptosis induction in MCL cells. There are currently no drugs that specifically target cancer stem cell fractions, and a reduction in BMI-1 protein by PTC596 may offer a novel therapeutic strategy for MCL.
36
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
Michael Wang, Simon Rule, Peter Martin et al. · New England Journal of Medicine · 2013 · 1.7K citations · Full text
Medicine, Hematology, Pharmacology +17
Self-renewal as a therapeutic target in human colorectal cancer
Antonija Kreso, Peter van Galen, Nicholas Pedley et al. · Nature Medicine · 2013 · 534 citations
Medicine, Cancer Biology, Oncology +14